Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

EJNMMI Physics

Caroline Stokke¹  Pablo Minguez Gabina²  Maria Paphiti³  Katarina Sjögreen Gleisner⁴  Pavel Solny⁵  Boudewijn Brans⁶  Mark Konijnenberg⁷  Mattias Sandström⁸  Glenn Flux⁹  Carlo Chiesa^1,10  Francesco Cicone^1,11  Emiliano Spezi^1,12  Jill Tipping^1,13 

[1] Department of Diagnostic Physics, Oslo University Hospital;Department of Medical Physics and Radiation Protection, Gurutzeta/Cruces University Hospital;Department of Medical Physics, Pammakaristos Hospital;Department of Medical Radiation Physics, Clinical Sciences Lund, Lund University;Department of Nuclear Medicine and Endocrinology, Motol University Hospital, 2nd Faculty of Medicine, Charles University;Department of Nuclear Medicine and PET Center, University Hospital;Department of Nuclear Medicine, Erasmus MC;Department of Surgical Sciences, Radiology, Uppsala University Hospital;Joint Department of Physics, Royal Marsden Hospital and Institute of Cancer Research;Nuclear Medicine Division, Foundation IRCCS Istituto Nazionale Tumori;Nuclear Medicine, Sant’Andrea Hospital, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome;School of Engineering, Cardiff University;The Christie NHS Foundation Trust, Nuclear Medicine;

关键词: Molecular radiotherapy;    Radionuclide therapy;    Radiopharmaceutical therapy;    European survey;    Dosimetry;   

DOI  :  10.1186/s40658-017-0193-4

来源: DOAJ

【 摘 要 】

Abstract Background Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. Methods An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Results Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for 90Y microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), 131I-NaI treatment of benign thyroid diseases (38% of responses), and for 131I-mIBG treatment of neuroblastoma (18% of responses). Conclusions There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.

【 授权许可】

Unknown